CoChat

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

Open access
Haber, Philipp K., Torres-Martin, Miguel, Dufour, Jean-Francois, Verslype, Chris, Marquardt, Jens, Galle, Peter R., Vogel, Arndt, Meyer, Tim, Labgaa, Ismail, Roberts, Lewis R., Minguez, Beatriz, Mazzaferro, Vincenzo, Finkelmeier, Fabian, Müller, Tobias, Schmelzle, Moritz, Finn, Richard S., Thung, Swan, Villanueva, Augusto, Sia, Daniela, Llovet, Josep M · 2021 · Journal of Clinical Oncology
Cited by 34

The DOI matches its Crossref record.

Abstract

4100 Background: Checkpoint inhibition with anti-PD1 is able to elicit objective response rates (ORR) of ̃ 20% in patients with advanced hepatocellular carcinoma (aHCC) but molecular biomarkers predicting response remain unknown. Here, we define biomarkers of response and primary resistance to anti-PD1 in aHCC by analyzing molecular features prior to systemic therapy. Methods: Through an international consortium of 13 referral centers, we gathered 111 fresh and archived tumor samples from patients with advanced HCC treated with single agent anti- PD1 therapy. Genomic analysis was performed with whole genome expression arrays, CTNNB1 exon 3 mutation assessment and histological evaluation. Results: Overall, we performed transcriptomic analysis in 83 patients, 28 of which were treated in first-line (ORR: 42.9%) while the remaining 55 patients were treated either in 2nd (41 patients, ORR 29.3%) or 3rd line (14 patients, ORR 7.1%) after prior therapy with tyrosine- kinase inhibitors (TKI) sorafenib or lenvatinib. In patients treated in frontline, response was associated with a significant upregulation in Interferon-γ signaling (IFNγ) and genesets relatedto the antigen presentation machinery (FDR < 0.05). Through differential expression analysis we defined an 11-gene signature that was significantly associated with both major pathways (FDR < 0.01) and was capable of predicting OR as well as progression-free- (PFS) and overall survival (OS) in patients with aHCC. The signature was validated in three independent cohorts of melanoma, lung cancer, and head and neck squamous cell cancer patients were high expression was associated with a significant increase in ORR and longer PFS. In HCC, high expression of the signature was associated with a distinct profile in the immune infiltrate, where an increase in M1 macrophages (p = 0.003), CD4 memory T cell (p < 0.01) and CD4 naïve T cell-infiltration (p = 0.026) was observed. Conversely, low expression of the signature was associated with a marked upregulation of regulatory T cells (p < 0.001). No association was found, however, between either the overall immune infiltrate or CTNNB1 mutations and response. In patients that were treated with TKIs in frontline before receiving subsequent anti-PD1 therapy, the signature was no longer able to predict either OR or PFS/OS, suggesting that TKIs may reshape the microenvironment in a way that renders previously inflamed tumors no longer amenable to anti-PD1. Conclusions: Here, we define an 11-gene signature of response to anti-PD1 in first line aHCC. The signature was validated in patients with other solid cancer types, where it retained its predictive ability. Of note, the signature was not able to identify responders among HCC patients that were treated with TKIs prior to anti-PD1 therapy. The molecular changes induced by different treatment lines would, thus, require fresh biopsies prior to anti-PD1to enable biomarker-driven treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2021.39.15_suppl.4100

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 34

Metadata

Authors
Haber, P. K., Torres-Martin, M., Dufour, J.-F., Verslype, C., Marquardt, J., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., Minguez, B., Mazzaferro, V., Finkelmeier, F., Müller, T., Schmelzle, M., Finn, R. S., Thung, S., Villanueva, A., Sia, D., & Llovet, J. M.
Venue
Journal of Clinical Oncology
Published
2021-05-20
Volume
39
Issue
15_suppl
Pages
4100-4100
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3168604477
Cited by
34
References
0
Type
conference abstract
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1200/jco.2021.39.15_suppl.4100
The paper
Haber, P. K., Torres-Martin, M., Dufour, J.-F., Verslype, C., Marquardt, J., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., Minguez, B., Mazzaferro, V., Finkelmeier, F., Müller, T., Schmelzle, M., Finn, R. S., Thung, S., Villanueva, A., Sia, D., & Llovet, J. M. (2021). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2021.39.15_suppl.4100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.